• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
In vitro activity of ceftolozane-tazobactam against Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals in the CANWARD study, 2007 to 2012.2007 年至 2012 年加拿大 CANWARD 研究中，从加拿大医院患者分离的铜绿假单胞菌对头孢洛扎-他唑巴坦的体外活性。
Antimicrob Agents Chemother. 2013 Nov;57(11):5707-9. doi: 10.1128/AAC.01404-13. Epub 2013 Aug 12.
2
Comparison of Ceftolozane-Tazobactam to Traditional Beta-Lactams and Ceftolozane-Tazobactam as an Alternative to Combination Antimicrobial Therapy for Pseudomonas aeruginosa.头孢他洛滨他唑巴坦与传统β-内酰胺类药物的比较以及头孢他洛滨他唑巴坦作为铜绿假单胞菌联合抗菌治疗替代方案的比较。
Antimicrob Agents Chemother. 2017 Nov 22;61(12). doi: 10.1128/AAC.01350-17. Print 2017 Dec.
3
Results from the China Antimicrobial Surveillance Network (CHINET) in 2017 of the Activities of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Clinical Isolates of and .2017 年中国抗菌药物监测网（CHINET）对临床分离的 和 的头孢他啶-阿维巴坦和头孢唑南-他唑巴坦活性研究结果。
Antimicrob Agents Chemother. 2019 Mar 27;63(4). doi: 10.1128/AAC.02431-18. Print 2019 Apr.
4
Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015).头孢洛扎/他唑巴坦对亚太地区（不包括中国、澳大利亚和新西兰）引起的医疗保健相关感染的耐药肠杆菌科和铜绿假单胞菌的活性：来自抗菌监测计划（2013-2015 年）的报告。
Int J Antimicrob Agents. 2018 Feb;51(2):181-189. doi: 10.1016/j.ijantimicag.2017.09.016. Epub 2017 Oct 6.
5
Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012).头孢洛扎/他唑巴坦对欧洲和美国医院腹腔内和尿路感染分离的需氧革兰氏阴性菌的活性检测（2012 年）。
J Infect. 2014 Sep;69(3):266-77. doi: 10.1016/j.jinf.2014.04.004. Epub 2014 Apr 26.
6
Antimicrobial Activity of Ceftolozane-Tazobactam Tested Against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2013-2016) as Part of the Surveillance Program: Program to Assess Ceftolozane-Tazobactam Susceptibility.作为监测项目“头孢洛扎-他唑巴坦敏感性评估项目”的一部分，对2013年至2016年在美国医院分离出的具有各种耐药模式的肠杆菌科细菌和铜绿假单胞菌进行头孢洛扎-他唑巴坦抗菌活性测试
Microb Drug Resist. 2018 Jun;24(5):563-577. doi: 10.1089/mdr.2017.0266. Epub 2017 Oct 17.
7
Multicenter Evaluation of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Inhibitory Activity against Meropenem-Nonsusceptible Pseudomonas aeruginosa from Blood, Respiratory Tract, and Wounds.多中心评估头孢他啶-阿维巴坦和头孢洛扎坦-他唑巴坦对血液、呼吸道和伤口来源的美罗培南不敏感铜绿假单胞菌的抑制活性。
Antimicrob Agents Chemother. 2017 Sep 22;61(10). doi: 10.1128/AAC.00875-17. Print 2017 Oct.
8
Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15).头孢洛扎/他唑巴坦对引起欧洲尿路感染和腹腔内感染的耐药肠杆菌科细菌及铜绿假单胞菌的活性：一项抗菌药物监测计划（2012 - 2015年）的报告
J Antimicrob Chemother. 2017 May 1;72(5):1386-1395. doi: 10.1093/jac/dkx009.
9
Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12).针对2011 - 12年在欧洲医院分离出的具有不同耐药模式的铜绿假单胞菌和肠杆菌科细菌测试头孢洛扎/他唑巴坦的抗菌活性。
J Antimicrob Chemother. 2014 Oct;69(10):2713-22. doi: 10.1093/jac/dku184. Epub 2014 Jun 10.
10
Comparison of antimicrobial activity between ceftolozane-tazobactam and ceftazidime-avibactam against multidrug-resistant isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa.头孢洛扎/他唑巴坦与头孢他啶/阿维巴坦对大肠埃希菌、肺炎克雷伯菌和铜绿假单胞菌多重耐药菌株抗菌活性的比较。
Int J Infect Dis. 2017 Sep;62:39-43. doi: 10.1016/j.ijid.2017.06.007. Epub 2017 Jun 10.

引用本文的文献

1
In-vitro activity of newly-developed β-lactamase inhibitors avibactam, relebactam and vaborbactam in combination with anti-pseudomonal β-lactam antibiotics against AmpC-overproducing clinical Pseudomonas aeruginosa isolates.新开发的β-内酰胺酶抑制剂阿维巴坦、瑞来巴坦和瓦博巴坦与抗假单胞菌β-内酰胺抗生素联合对产AmpC临床铜绿假单胞菌分离株的体外活性。
Eur J Clin Microbiol Infect Dis. 2025 Feb;44(2):277-284. doi: 10.1007/s10096-024-04965-x. Epub 2024 Nov 26.
2
Prevalence of colistin resistance in clinical isolates of : a systematic review and meta-analysis.临床分离株中黏菌素耐药性的流行情况：一项系统评价和荟萃分析。
Front Microbiol. 2024 Oct 9;15:1477836. doi: 10.3389/fmicb.2024.1477836. eCollection 2024.
3
Comparative In Vitro Activity of Ceftolozane/Tazobactam against Clinical Isolates of and from Five Latin American Countries.头孢洛扎/他唑巴坦对来自五个拉丁美洲国家的[具体细菌名称缺失]临床分离株的体外活性比较
Antibiotics (Basel). 2022 Aug 13;11(8):1101. doi: 10.3390/antibiotics11081101.
4
A Prospective Randomized Study Comparing Ceftolozane/Tazobactam to Standard of Care in the Management of Neutropenia and Fever in Patients With Hematological Malignancies.一项比较头孢洛扎/他唑巴坦与标准治疗方案用于治疗血液系统恶性肿瘤患者中性粒细胞减少和发热的前瞻性随机研究。
Open Forum Infect Dis. 2022 Feb 14;9(6):ofac079. doi: 10.1093/ofid/ofac079. eCollection 2022 Jun.
5
New β-Lactam-β-Lactamase Inhibitor Combinations.新型β-内酰胺类-β-内酰胺酶抑制剂复方制剂
Clin Microbiol Rev. 2020 Nov 11;34(1). doi: 10.1128/CMR.00115-20. Print 2020 Dec 16.
6
Real-World Experience with Ceftolozane-Tazobactam for Multidrug-Resistant Gram-Negative Bacterial Infections.头孢他啶阿维巴坦治疗多重耐药革兰阴性菌感染的真实世界经验
Antimicrob Agents Chemother. 2020 Mar 24;64(4). doi: 10.1128/AAC.02291-19.
7
The latest advances in β-lactam/β-lactamase inhibitor combinations for the treatment of Gram-negative bacterial infections.β-内酰胺/β-内酰胺酶抑制剂复方制剂在治疗革兰氏阴性菌感染方面的最新进展。
Expert Opin Pharmacother. 2019 Dec;20(17):2169-2184. doi: 10.1080/14656566.2019.1660772. Epub 2019 Sep 9.
8
Activity of Ceftolozane/Tazobactam Against Gram-Negative Rods of the Family Enterobacteriaceae and Pseudomonas Spp. Isolated from Onco-Hematological Patients Hospitalized in a Clinical Hospital in Poland.头孢他洛滨/他唑巴坦对从波兰一家临床医院住院的血液肿瘤患者中分离出的肠杆菌科和假单胞菌属革兰氏阴性杆菌的活性。
Med Sci Monit. 2019 Jan 10;25:305-311. doi: 10.12659/MSM.913352.
9
β-lactam/β-lactamase inhibitor combinations: an update.β-内酰胺类/β-内酰胺酶抑制剂联合制剂：最新进展
Medchemcomm. 2018 Aug 17;9(9):1439-1456. doi: 10.1039/c8md00342d. eCollection 2018 Sep 1.
10
Intravenous Fosfomycin: An Assessment of Its Potential for Use in the Treatment of Systemic Infections in Canada.静脉注射磷霉素：对其在加拿大用于治疗全身性感染的潜力评估。
Can J Infect Dis Med Microbiol. 2018 Jun 25;2018:8912039. doi: 10.1155/2018/8912039. eCollection 2018.

本文引用的文献

1
Antimicrobial susceptibility of Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals: CANWARD 2008-2011.2008-2011 年加拿大医院分离的铜绿假单胞菌的药敏情况：CANWARD 研究。
Diagn Microbiol Infect Dis. 2012 Aug;73(4):361-4. doi: 10.1016/j.diagmicrobio.2012.05.007. Epub 2012 Jun 12.
2
Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes.CXA-101 是一种新型头孢菌素，与他唑巴坦联合测试对具有不同耐药表型的肠杆菌科、铜绿假单胞菌和脆弱拟杆菌菌株的抗菌活性。
Antimicrob Agents Chemother. 2011 May;55(5):2390-4. doi: 10.1128/AAC.01737-10. Epub 2011 Feb 14.
3
Multidrug-resistant Pseudomonas aeruginosa bloodstream infections: risk factors and mortality.多重耐药铜绿假单胞菌血流感染：危险因素和死亡率。
Epidemiol Infect. 2011 Nov;139(11):1740-9. doi: 10.1017/S0950268810003055.
4
Prevalence of antimicrobial-resistant pathogens in Canadian hospitals: results of the Canadian Ward Surveillance Study (CANWARD 2008).加拿大医院中抗微生物药物耐药病原体的流行情况：加拿大病房监测研究（CANWARD 2008）的结果。
Antimicrob Agents Chemother. 2010 Nov;54(11):4684-93. doi: 10.1128/AAC.00469-10. Epub 2010 Aug 30.
5
Impact of multidrug-resistant Pseudomonas aeruginosa bacteremia on patient outcomes.多重耐药铜绿假单胞菌菌血症对患者结局的影响。
Antimicrob Agents Chemother. 2010 Sep;54(9):3717-22. doi: 10.1128/AAC.00207-10. Epub 2010 Jun 28.
6
Affinity of the new cephalosporin CXA-101 to penicillin-binding proteins of Pseudomonas aeruginosa.新型头孢菌素 CXA-101 对铜绿假单胞菌青霉素结合蛋白的亲和力。
Antimicrob Agents Chemother. 2010 Sep;54(9):3933-7. doi: 10.1128/AAC.00296-10. Epub 2010 Jun 14.
7
Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients.新型头孢菌素 CXA-101（FR264205）对体外筛选和重症监护病房患者抗假单胞菌治疗后产生的β-内酰胺耐药铜绿假单胞菌突变株的活性。
Antimicrob Agents Chemother. 2010 Mar;54(3):1213-7. doi: 10.1128/AAC.01104-09. Epub 2010 Jan 19.
8
Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains.新型抗假单胞菌头孢菌素 CXA-101（FR264205）对耐碳青霉烯类和多药耐药铜绿假单胞菌临床分离株的活性。
Antimicrob Agents Chemother. 2010 Feb;54(2):846-51. doi: 10.1128/AAC.00834-09. Epub 2009 Nov 23.
9
In vitro potency of CXA-101, a novel cephalosporin, against Pseudomonas aeruginosa displaying various resistance phenotypes, including multidrug resistance.新型头孢菌素 CXA-101 对呈现各种耐药表型（包括多重耐药）的铜绿假单胞菌的体外效力。
Antimicrob Agents Chemother. 2010 Jan;54(1):557-9. doi: 10.1128/AAC.00912-09. Epub 2009 Nov 16.
10
Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America.有害病菌，无药可医：谨防“ESKAPE”！美国传染病学会的最新报告
Clin Infect Dis. 2009 Jan 1;48(1):1-12. doi: 10.1086/595011.

2007 年至 2012 年加拿大 CANWARD 研究中，从加拿大医院患者分离的铜绿假单胞菌对头孢洛扎-他唑巴坦的体外活性。

In vitro activity of ceftolozane-tazobactam against Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals in the CANWARD study, 2007 to 2012.

机构信息

Departments of Medicine and Clinical Microbiology, Health Sciences Centre.

出版信息

Antimicrob Agents Chemother. 2013 Nov;57(11):5707-9. doi: 10.1128/AAC.01404-13. Epub 2013 Aug 12.

DOI:10.1128/AAC.01404-13
PMID:23939895
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3811242/
Abstract

The in vitro activity of ceftolozane in combination with tazobactam (fixed concentration of 4 μg/ml) was evaluated against 2,435 Pseudomonas aeruginosa clinical isolates obtained from across Canada using Clinical and Laboratory Standards Institute broth microdilution methods. The MIC50 and MIC90 values for ceftolozane-tazobactam were 0.5 μg/ml and 1 μg/ml, respectively (a 32-fold-lower MIC90 than that for ceftazidime). Eighty-nine percent (141/158) of multidrug-resistant isolates were inhibited by ≤8 μg/ml of ceftolozane-tazobactam.

摘要

采用临床和实验室标准协会肉汤微量稀释法，评估了头孢洛扎他唑巴坦（固定浓度为 4μg/ml）组合对来自加拿大各地的 2435 株铜绿假单胞菌临床分离株的体外活性。头孢洛扎他唑巴坦的 MIC50 和 MIC90 值分别为 0.5μg/ml 和 1μg/ml（MIC90 比头孢他啶低 32 倍）。89%（141/158）的多重耐药分离株被≤8μg/ml 的头孢洛扎他唑巴坦抑制。